Apogenix GmbH, a biopharmaceutical company, has announced that APG101, designed for the 2nd line treatment of glioblastoma multiforme (GBM), has met its primary endpoint 6 months after the follow-up of the last treated patient...
Júlio Leonardo B. Pereira
No comments:
Post a Comment